(CSTL) Castle Biosciences - Ratings and Ratios
Melanoma, Squamous, Uveal, Barrett, Pharmacogenomic
CSTL EPS (Earnings per Share)
CSTL Revenue
Description: CSTL Castle Biosciences October 23, 2025
Castle Biosciences, Inc. (NASDAQ:CSTL) is a molecular-diagnostics firm that commercializes gene-expression and spatial-omics tests aimed at stratifying risk and guiding treatment for dermatologic cancers, Barrett’s esophagus, uveal melanoma, and several psychiatric disorders.
Key product lines include DecisionDx-Melanoma and DecisionDx-UM (risk-stratification for cutaneous and uveal melanoma), DecisionDx-SCC (cutaneous squamous cell carcinoma), MyPath Melanoma (diagnostic aid for ambiguous lesions), TissueCypher (predictive assay for progression of Barrett’s esophagus), and IDgenetix (pharmacogenomic panel for major mental-health conditions). The company primarily serves dermatology and gastroenterology markets in the United States.
Recent performance metrics (Q3 2024) show revenue of $13.2 million, a 19 % year-over-year increase driven by higher test adoption in dermatology, and a cash position of roughly $150 million, providing runway for R&D and potential acquisition targets. The firm’s market cap sits near $550 million, implying a price-to-sales multiple of ~41×, which is elevated relative to the broader biotech median (~12×) and reflects the premium investors place on its niche diagnostic franchise.
Sector drivers that could materially affect Castle’s outlook include: (1) an aging U.S. population and rising UV exposure, which are expanding the incidence pool for skin cancers; (2) evolving Medicare reimbursement policies that increasingly favor molecular-diagnostic tests with demonstrated clinical utility; and (3) competitive pressure from larger diagnostics players (e.g., Guardant Health, Roche) that are accelerating their own dermatology assay pipelines.
For a deeper quantitative assessment of CSTL’s valuation metrics and peer comparison, the ValueRay platform offers a concise dashboard that can help you gauge the stock’s risk-adjusted upside.
CSTL Stock Overview
| Market Cap in USD | 689m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-07-25 |
CSTL Stock Ratings
| Growth Rating | -7.01% |
| Fundamental | 58.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -13.0% |
| Analyst Rating | 4.89 of 5 |
CSTL Dividends
Currently no dividends paidCSTL Growth Ratios
| Growth Correlation 3m | 66.3% |
| Growth Correlation 12m | -42.3% |
| Growth Correlation 5y | -64.4% |
| CAGR 5y | 13.95% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.24 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.52 |
| Sharpe Ratio 12m | -0.30 |
| Alpha | -13.47 |
| Beta | 1.131 |
| Volatility | 95.24% |
| Current Volume | 375.5k |
| Average Volume 20d | 254.9k |
| Stop Loss | 31.7 (-4.1%) |
| Signal | 0.87 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-9.47m TTM) > 0 and > 6% of Revenue (6% = 20.8m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 86.00% (prev 97.69%; Δ -11.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 62.5m > Net Income -9.47m (YES >=105%, WARN >=100%) |
| Net Debt (-44.9m) to EBITDA (25.0m) ratio: -1.79 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.5m) change vs 12m ago 2.81% (target <= -2.0% for YES) |
| Gross Margin 80.27% (prev 79.06%; Δ 1.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.10% (prev 59.02%; Δ 8.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -52.75 (EBITDA TTM 25.0m / Interest Expense TTM 331.0k) >= 6 (WARN >= 3) |
Altman Z'' -0.57
| (A) 0.55 = (Total Current Assets 348.7m - Total Current Liabilities 50.9m) / Total Assets 544.7m |
| (B) -0.41 = Retained Earnings (Balance) -221.5m / Total Assets 544.7m |
| (C) -0.03 = EBIT TTM -17.5m / Avg Total Assets 516.0m |
| (D) -2.48 = Book Value of Equity -221.4m / Total Liabilities 89.4m |
| Total Rating: -0.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.48
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.67% = 3.84 |
| 3. FCF Margin 9.97% = 2.49 |
| 4. Debt/Equity 0.08 = 2.50 |
| 5. Debt/Ebitda -1.79 = 2.50 |
| 6. ROIC - WACC (= -17.67)% = -12.50 |
| 7. RoE -2.11% = -0.35 |
| 8. Rev. Trend 94.83% = 7.11 |
| 9. EPS Trend 57.88% = 2.89 |
What is the price of CSTL shares?
Over the past week, the price has changed by +29.57%, over one month by +44.15%, over three months by +68.14% and over the past year by -0.81%.
Is Castle Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CSTL is around 30.78 USD . This means that CSTL is currently overvalued and has a potential downside of -6.84%.
Is CSTL a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CSTL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.6 | 7.8% |
| Analysts Target Price | 35.6 | 7.8% |
| ValueRay Target Price | 34.7 | 4.9% |
CSTL Fundamental Data Overview October 31, 2025
P/S = 1.9888
P/B = 1.4161
Beta = 1.131
Revenue TTM = 346.3m USD
EBIT TTM = -17.5m USD
EBITDA TTM = 25.0m USD
Long Term Debt = 8.10m USD (from longTermDebt, last quarter)
Short Term Debt = 3.52m USD (from shortTermDebt, last quarter)
Debt = 37.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -44.9m USD (from netDebt column, last quarter)
Enterprise Value = 450.1m USD (688.7m + Debt 37.4m - CCE 275.9m)
Interest Coverage Ratio = -52.75 (Ebit TTM -17.5m / Interest Expense TTM 331.0k)
FCF Yield = 7.67% (FCF TTM 34.5m / Enterprise Value 450.1m)
FCF Margin = 9.97% (FCF TTM 34.5m / Revenue TTM 346.3m)
Net Margin = -2.73% (Net Income TTM -9.47m / Revenue TTM 346.3m)
Gross Margin = 80.27% ((Revenue TTM 346.3m - Cost of Revenue TTM 68.3m) / Revenue TTM)
Gross Margin QoQ = 76.64% (prev 81.38%)
Tobins Q-Ratio = 0.83 (Enterprise Value 450.1m / Total Assets 544.7m)
Interest Expense / Debt = 0.06% (Interest Expense 21.0k / Debt 37.4m)
Taxrate = 3263 % (out of range, set to none) (-4.67m / -143.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 6.85 (Total Current Assets 348.7m / Total Current Liabilities 50.9m)
Debt / Equity = 0.08 (Debt 37.4m / totalStockholderEquity, last quarter 455.4m)
Debt / EBITDA = -1.79 (Net Debt -44.9m / EBITDA 25.0m)
Debt / FCF = -1.30 (Net Debt -44.9m / FCF TTM 34.5m)
Total Stockholder Equity = 448.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.74% (Net Income -9.47m / Total Assets 544.7m)
RoE = -2.11% (Net Income TTM -9.47m / Total Stockholder Equity 448.1m)
RoCE = -3.83% (EBIT -17.5m / Capital Employed (Equity 448.1m + L.T.Debt 8.10m))
RoIC = -8.01% (negative operating profit) (EBIT -17.5m / (Assets 544.7m - Curr.Liab 50.9m - Cash 275.9m))
WACC = 9.66% (E(688.7m)/V(726.0m) * Re(10.18%) + (debt cost/tax rate unavailable))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.55%
[DCF Debug] Terminal Value 62.53% ; FCFE base≈31.0m ; Y1≈21.2m ; Y5≈10.5m
Fair Price DCF = 5.11 (DCF Value 148.4m / Shares Outstanding 29.0m; 5y FCF grow -37.01% → 3.0% )
EPS Correlation: 57.88 | EPS CAGR: 53.31% | SUE: 1.17 | # QB: 2
Revenue Correlation: 94.83 | Revenue CAGR: 35.99% | SUE: 2.61 | # QB: 2
Additional Sources for CSTL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle